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Abstract: Development of selective inhibitors of BRAF has improved the survival of patients 
with BRAF-mutant melanoma. The progression-free survival after treatment with a BRAF 
inhibitor is modest, however, and BRAF inhibitors induce cutaneous toxicity, likely due to 
paradoxical activation of the mitogen-activated protein kinase pathway. Combining selective 
BRAF and MEK inhibition, such as the BRAF inhibitor dabrafenib and the MEK inhibitor 
trametinib, has been shown to improve the response rate and progression-free survival in 
patients with advanced melanoma while significantly alleviating the paradoxical activation of 
mitogen-activated protein kinase. This combination treatment results in a reduction in skin toxic-
ity relative to that seen with a BRAF inhibitor alone; however, addition of the MEK inhibitor 
adds other toxicities, such as pyrexia and gastrointestinal or ocular toxicity. While combined 
BRAF–MEK inhibition appears primed to become a standard molecular approach for BRAF-
mutant melanoma, the utility of the combination has to be considered in the rapidly changing 
landscape of immunotherapeutics, such as immune checkpoint blockade using anti-cytotoxic 
T lymphocyte antigen-4 and anti-programmed death-1/programmed death-L1 antibodies. Here 
we review the development of the dabrafenib plus trametinib combination, the characteristics of 
each drug and the combination, and the role of this combination in the management of patients 
with BRAF-mutant melanoma.
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Introduction
Malignant melanoma is among the most lethal of the cutaneous neoplasms. In the 
USA, the annual incidence of melanoma in 2010 was approximately 70,230 cases 
according to Surveillance, Epidemiology, and End Results data.1 The incidence of 
melanoma has been rising over the past few decades.2 Multiple risk factors for the 
development of melanoma have been proposed; however, the only parameter that 
has been consistently associated with development of melanoma is ultraviolet light 
exposure.3,4 The outcomes are good for patients diagnosed with early-stage disease, 
with 5-year   recurrence rates of ,10% for stage I patients. However, as stages progress, 
disease-free survival rates begin to decrease significantly, such that patients rendered 
disease-free but who are stage IIIC have 5-year recurrence rates of 70%–80%.5
Outcomes continue to be poor for most patients with metastatic disease. Prior to 
2011, the diagnosis of unresectable, advanced malignant melanoma carried a prognosis 
that included a 5-year survival of 6% and a median survival of 7.5 months.6,7 Since 
2011, two major advances have come into clinical practice, ie, immune-checkpoint 
blockade and targeting of the BRAFV600 protein in patients harboring this mutation. Drug, Healthcare and Patient Safety 2014:6 submit your manuscript | www.dovepress.com
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Advances in immunotherapy were initially spurred with the 
development of ipilimumab (Bristol-Myers Squibb, Princeton, 
NJ, USA), the human anti-cytotoxic T lymphocyte antigen-4 
(CTLA-4) monoclonal antibody. This drug was demonstrated 
to improve survival in two Phase III clinical trials.8,9 In studies 
of ipilimumab, objective radiographic responses at preselected 
time points occurred in 8%–15% of patients, with an overall 
response rate of 10%–20%.10–12 Further, improvements in over-
all survival were observed in patients with advanced melanoma 
when ipilimumab was compared with a gp100 vaccine8 and 
when the combination of ipilimumab plus dacarbazine was 
compared with dacarbazine alone.9 Moving forward, two anti-
programmed death-1 (PD-1) receptor antibodies, nivolumab 
(Bristol-Myers Squibb) and MK-3475 (Merck, Whitehouse 
Station, NJ, USA) are also likely to be approved for the treat-
ment of advanced melanoma in the next few years. These 
immunotherapies demonstrate higher response rates and an 
impressive safety profile, with preliminary data suggesting 
an improvement in overall survival, while Phase III data from 
the clinical trials are not yet mature.13
Regarding BRAF-directed therapy, the BRAF inhibitor 
vemurafenib (F Hoffmann-La Roche Ltd, Basel, Switzerland) 
was also shown to significantly improve overall survival 
in patients with advanced melanoma in a Phase III trial,14 
with a 30% improvement as compared with dacarbazine.15 
Notably, the response rate of vemurafenib was much higher 
(approximately 50%) when compared with chemotherapy 
(dacarbazine); however, nearly all patients eventually had 
progression of melanoma on BRAF inhibitor therapy. These 
clinical gains have significantly advanced the care of patients 
with melanoma; however, they are not applicable to all 
patients. As such, the median overall survival of this popula-
tion continues to be likely less than 2 years.16
While BRAF targeting has a high response rate, the benefit 
in terms of progression-free survival appears to be finite in 
nearly all patients with melanoma. To address the eventual 
progression of melanoma while on a BRAF inhibitor, rational 
approaches have been studied to improve the therapeutic poten-
tial and durability of BRAF inhibition. An important step in this 
regard has been the addition of concurrent downstream inhibi-
tion of the mitogen-activated protein kinase (MAPK) pathway 
at MEK in conjunction with BRAF. Dual BRAF–MEK inhi-
bition by dabrafenib and trametinib (both GlaxoSmithKline, 
Philadelphia, PA, USA) in BRAFV600E/K-mutant melanoma 
has been observed to be more durable as compared with 
monotherapy using a BRAF inhibitor.17 This drug combina-
tion received fast-track approval from the US Food and Drug 
Administration (FDA) in 2014 and is now available in standard 
clinical practice. Here we review the biology of BRAF and the 
rationale for this combination therapy, the pharmacology and 
mechanisms of action of these drugs, the clinical efficacy and 
toxicity associated with these agents, the potential implications 
regarding quality of life and patient satisfaction, and finally the 
role of this drug combination in the management of advanced 
BRAF-mutant melanoma.
BRAF biology and rationale  
for combination
With the increase in molecular profiling of human tumor 
specimens, mutations that are common across multiple 
malignancies are increasingly being recognized. Some of 
these are potentially targetable with molecular therapeutics, 
and may necessitate the advent of a new paradigm in which 
the molecular phenotype of a tumor is treated as opposed 
to its site of origin. Mutations in the BRAF oncogene may 
be an example of this. BRAF mutations have been charac-
terized to constitute up to approximately 60% of the driver 
lesions in cutaneous melanoma,18,19 and they have also been 
observed in several other tumor types. More specifically, 
BRAF mutations have been characterized in 10%–15% of 
colorectal carcinomas,18 3% of lung adenocarcinomas20 and 
breast cancers,21 20%–50% of serous ovarian cancers,22–24 
and 29%–69% of papillary thyroid cancers.25,26 In addition, 
BRAF mutations may confer a worse clinical prognosis in 
several of these tumor types compared with cancers with-
out the BRAF mutation.27,28 In melanoma, the presence of 
BRAF mutation in the primary lesion has not been shown 
to impact on disease-free interval (time to metastasis) or 
overall survival.29,30 However, after the development of 
metastatic melanoma, the median survival of patients with 
BRAF mutations has been described as shorter relative to 
patients with wild-type BRAF tumors, although this appears 
no longer to be the case given the development of selective 
BRAF inhibitors.31
Multiple laboratory and clinical reports have started to 
detail mechanisms of both primary and acquired resistance 
to BRAFV600E inhibition in malignant melanoma.32,33 These 
mechanisms include acquired NRAS mutations, activation of 
non-MAPK growth pathways such as phosphatidylinositol 
3-kinase/AKT34 via receptor tyrosine kinases (ie, platelet-
derived growth factor receptor-β), overexpression of 
COT kinase,35 mutation of MEK,36 development of RAS-
independent BRAFV600E isoform splice variants,37 BRAF 
amplification,38 and overexpression of hepatocyte growth 
factor/activation of MET.39 Adaptive upregulation of the AKT 
pathway has also been shown to modulate the utility of BRAF Drug, Healthcare and Patient Safety 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
79
Dabrafenib-trametinib in metastatic melanoma
inhibitors in patients.40 These mechanisms of resistance are 
shown in Figure 1.
Mechanisms of resistance to treatment with BRAF 
inhibitors have recently been published in larger cohorts 
demonstrating approximately 50%–70% as harboring MAPK 
reactivating changes, with RAS mutations, amplification of 
BRAF, and BRAF splice variants being the most common.41,42 
Mutations not previously described but thought likely to reac-
tivate MAPK were also discovered, and include MAP2K2, 
MITF, and NF1, as well as mutations with less clear relevance 
to MAPK, such as HOXD8 and RAC1.42 Alterations in the 
phosphatidylinositol 3-kinase/AKT pathway were also 
observed in approximately 20% of patients.41,42
The outcomes for patients with BRAF-mutant melanoma 
after development of resistance to BRAF targeting are poor, 
and there are preliminary data suggesting that these patients 
deteriorate faster than patients not treated with vemurafenib. 
In a post hoc analysis of the Phase I study of vemurafenib 
presented at the 2011 American Society of Clinical   Oncology 
meeting, 18 of 48 patients were allowed to continue the study 
drug beyond the development of initial resistance after receiv-
ing local therapy to control isolated disease progression.43 
In this group, the median overall survival was not reached 
during a follow-up period of 15.5 months from initiation 
of vemurafenib and median overall survival from the time 
of initial progressive disease was also not reached (median 
follow-up of 6.0 months). For the 28 patients who did not 
continue treatment with vemurafenib after progression, the 
median overall survival after development of resistance was 
1.4 months.43 This analysis also detailed the sites of progres-
sion after development of resistance, with a notable finding 
that 25% of patients had disease progression in the brain and 
central nervous system (19% of patients had metastasis to 
the brain as the only site). Similarly, an analysis of patient 
outcomes in advanced BRAF-mutant melanoma showed 
that patients receiving BRAF inhibitor therapy prior to 
immunotherapy had worse outcomes when compared with 
the opposite approach of immunotherapy followed by BRAF 
inhibitor therapy.44 These data are consistent with models of 
molecular resistance which suggest that upon removal of 
inhibition of the primary oncogenic kinase pathway (such as 
BRAF in melanoma), patients experience a tumor flare as the 
kinase is reactivated.45–47
The molecular biology of mutant RAF signaling is 
complex, and significant efforts have been made to eluci-
date it. Briefly, RAS is activated upon upstream activation 
of receptor tyrosine kinase, leading to signal transduction 
through wild-type RAF isoforms (including BRAF, CRAF, 
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Figure 1 Mechanisms of resistance to BRAF inhibitor treatment.
Abbreviations: HGF, hepatocyte growth factor; mTOR, mammalian target of rapamycin; Pi3K, phosphoinositide 3-kinase; RTKs, receptor tyrosine kinases, MAPK, mitogen-
activated protein kinase; eGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; iGF-1R, insulin-like growth factor 1 receptor; FGFR, 
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and ARAF). These RAF isoforms produce homodimers and 
heterodimers in different combinations (eg, BRAF: BRAF, 
BRAF: CRAF, etc). These dimer complexes then lead to 
activation of MEK1 or MEK2, with subsequent signaling 
through activation of the ERK and MAPK pathways. In 
contrast, mutated BRAF exists as a monomer and signals in 
constitutive fashion independent of upstream activation by 
receptor tyrosine kinase and RAS. Vemurafenib blocks this 
activation of mutant BRAF but “paradoxically” can also 
lead to downstream MEK activation in physiologic MAPK 
(non-BRAF-mutated cells) cells through ARAF or CRAF 
homodimerization and heterodimerization.48 This is caused 
by transactivation of the non-drug-bound partner in BRAF 
to CRAF heterodimers or CRAF to CRAF homodimers by 
BRAF inhibitors.49 This process is described in Figure 2.
These various RAF dimers, and especially the paradoxical 
downstream activation of MEK by nonmutant RAF dimers, 
help to explain some of the mechanisms of vemurafenib 
resistance and also shed light on the initially unexpected side 
effects of keratoacanthoma and cutaneous squamous cell 
carcinoma. Activation of MEK after inhibition of BRAF by 
vemurafenib is mediated by dimerization of BRAF to CRAF, 
leading to subsequent CRAF signaling.50,51 There is some 
suggestion that this may occur in a dose-dependent fashion.49 
Further, it is now apparent that upstream activation of RAS, 
predominantly by HRAS mutation, significantly promotes 
this effect in non-BRAF-mutant tissues.52 Activation of RAS 
is not unexpected in the skin, given the prevalence of such 
mutations due to ultraviolet light exposure from the sun.
Given that the mechanisms of BRAF inhibitor resistance 
overwhelmingly reactivate MAPK as well as the observation 
of RAF-induced skin effects, there has been interest in com-
bining oncogenic BRAF inhibition with downstream MAPK 
inhibition, such as a MEK inhibitor. Preclinical evaluations 
of BRAF plus MEK inhibition in cell lines and xenografts 
that have acquired resistance to BRAFV600E targeting have 
demonstrated that the combination is active.53 Further, 
combined BRAF–MEK inhibition has been shown to induce 
greater cell killing and to allow a longer time to development 
of resistance than treatment with a BRAF or MEK inhibitor 
alone in naïve BRAFV600E-mutant melanoma models. Also of 
note is that preclinical rat models of the combination therapy 
have demonstrated that development of keratoacanthoma 
and squamous cell carcinoma appears to be abrogated to a 
significant degree by the combination54 and clinical toxicity 
data bear this out.55 Most importantly, the Phase I–II clinical 
trial of dabrafenib and trametinib showed impressive effi-
cacy in terms of response rate and progression-free survival 
for the combination.17 While pending further validation 
in Phase III trials, these preliminary data demonstrated a 
median progression-free survival at the highest dose for the 
BRAF–MEK combination arm of 9.4 months (dabrafenib 
150 mg twice per day, trametinib 2 mg daily), as compared 
with 5.8 months in the BRAF monotherapy group. Further, 
the rate of complete or partial response with BRAF–MEK 
combination therapy was 76%, as compared with 54% with 
BRAF monotherapy. As such, the combination of BRAF 
plus MEK inhibition by dabrafenib plus trametinib appears 
to be an improvement on single-agent BRAF inhibition. 
Early efforts have been made to examine the mechanisms 
of resistance to BRAF–MEK combination therapy, with the 
first report revealing that reactivation of MAPK continues 
to be the major driver of resistance. In three of five samples 
from patients who had become resistant to the combination, 
a novel mutation in MEK2 (Q60P) was observed, while two 
previously described mechanisms to single-agent BRAF 
inhibitor, BRAF splice variant and BRAF amplification, 
were observed.56 Why treatment with a MEK inhibitor did 
not overcome these mechanisms is not clear; however, this 
suggests that further investigations regarding the optimal 
approach to inhibit the MAPK pathway in BRAF-mutant 
melanoma are in order.
Pharmacology and mechanism of 
action of dabrafenib and trametinib
Pharmacokinetics of dabrafenib
Dabrafenib has a median terminal half-life of approximately 
8 hours after a single dose, with plasma concentrations 
peaking at a median of 2 hours and declining thereafter.57 In 
single-dose studies, the peak concentration and area under 
the curve were dose-proportional through 300 mg of dose 
escalation. At the approved dose of dabrafenib (150 mg twice 
per day), the peak concentration and area under the curve 
were approximately 40% lower by day 15 as compared with 
day 8. Despite this, the area under the curve appears to remain 
stable thereafter with subsequent dosing. The mechanism for 
this decrease is not clear, but may relate to autoinduction 
pharmacokinetics by dabrafenib itself.
The metabolism of dabrafenib is predominantly hepatic, 
with preclinical studies suggesting that the cytochrome 
P450 (CYP) superfamily of mono-oxygenases plays a major 
role. More specifically, CYP2C8 and CYP3A4 appear to 
be the predominant enzymes; however, CYP2C19 may 
also contribute. Dabrafenib is also a substrate for ATP-
binding cassette subfamily B member 1 and G member 2, 
also known as multidrug resistance protein 1 and breast Drug, Healthcare and Patient Safety 2014:6 submit your manuscript | www.dovepress.com
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Figure 2 Paradoxical activation of the MAPK pathway. 
Notes: (A) Constitutively upregulated MAPK signaling by monomeric mutant BRAF (BRAFv600) is blocked by BRAF-specific inhibition using a selective BRAF inhibitor such 
as vemurafenib or dabrafenib. (B) In normal and tumor RAF wild-type cells, BRAF specific inhibition leads to paradoxic upregulation of the MAPK pathway. In these cells 
RAS activity is high, leading to RAF homodimerization or heterodimerization (eg, BRAF: BRAF, BRAF: CRAF, etc). BRAF-specific inhibition results in transactivation of the 
homodimeric or heterodimeric binding partner and increased downstream MAPK signaling.
Abbreviations: ATP, adenosine triphosphate; MAPK, mitogen-activated protein kinase; RTK, receptor tyrosine kinases; vem, vemurafenib; Dab, dabrafenib; eGFR, epidermal 
growth factor receptor; PDGFR, platelet-derived growth factor receptor; iGF-1R, insulin-like growth factor 1 receptor; FGFR, fibroblast growth factor receptor.
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cancer resistance protein, respectively. As such, drugs that 
are strong inducers of these CYPs or transport proteins are 
contraindicated during treatment with dabrafenib, and care 
must be taken when administering other drugs metabolized 
by these pathways.
The major route of excretion of dabrafenib in humans is 
fecal (.70%), while renal excretion accounts for less than 20%. 
The effects of fatty foods on the absorption of dabrafenib have 
been somewhat equivocal; however, it is currently recom-
mended that dabrafenib be taken on an empty stomach.Drug, Healthcare and Patient Safety 2014:6 submit your manuscript | www.dovepress.com
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Pharmacokinetics of trametinib
Trametinib has a median terminal half-life of approximately 
4.5 days after a single dose, with plasma concentrations 
peaking at a median of one and a half days.58 In single-dose 
studies, the peak concentration and area under the curve were 
dose-proportional through dose escalation of up to 6 mg. At 
the approved dose of trametinib (2 mg daily), the peak con-
centration and area under the curve were significantly influ-
enced by fatty meals, with an approximately 70% decrease 
in peak concentration and a 10% decrease in area under the 
curve when compared with fasting. Trametinib demonstrates 
a small peak to trough ratio of approximately 2 which, in the 
context of the extended half-life, allows more constant MEK 
inhibition within a narrow range of exposure.59
As opposed to dabrafenib, the metabolism of trametinib is 
predominantly nonhepatic, involving deacetylation as well as 
secondary modifications including oxidation and glucuroni-
dation. Trametinib does not appear to have significant inhibi-
tory activity toward CYP isozymes or transport proteins, thus 
limiting potential drug–drug interactions.
Pharmacokinetics of dabrafenib  
and trametinib
Dabrafenib has a somewhat higher plasma exposure in 
combination with trametinib, although this finding does not 
appear to be clinically significant and no clear rationale has 
yet been advanced to explain it. The pharmacokinetics of 
trametinib does not appear to be influenced when given in 
combination with dabrafenib.
Mechanism of action of dabrafenib  
and trametinib
Dabrafenib is an ATP-competitive, selective inhibitor of RAF 
kinases, with the strongest effect being on mutant BRAFV600   
relative to wild-type BRAF or CRAF.   Dabrafenib has minor 
activity (50% inhibitory concentration ,100 nM) against a 
small number of other kinases, including LIMK1, ALK5, 
NEK11, SIK, SIK2, PKD2, and BRK. Trametinib is an 
allosteric, ATP-noncompetitive inhibitor of MEK1 and 
MEK2 at subnanomolar concentrations. Trametinib did not 
have significant effects on other kinases when compared in 
a 183 kinase panel.60
Safety and efficacy of dabrafenib 
and trametinib as single agents  
and in combination
Dabrafenib is the second BRAF inhibitor approved by the 
FDA less than 2 years after vemurafenib. An initial Phase I 
study of patients with solid tumors harboring BRAFV600E/K 
mutations examined escalating doses of dabrafenib in 
184 patients. The recommended Phase II dose of 150 mg 
twice daily was established despite no observed maximum 
tolerated dose.61 Common toxicities included photosensi-
tivity, rash, and fatigue, similar to vemurafenib. Serious 
adverse events were reported in 39% of patients, specifi-
cally noting rash (13%), squamous cell carcinoma (11%), 
and pyrexia (6%). Pyrexia was the most common adverse 
event leading to dose interruption. Tumor shrinkage was 
observed in nine of ten patients with previously untreated 
brain metastases.61 A Phase II study (known as BREAK-MB,   
ClinicalTrials.gov identifier NCT01266967) evaluated the use 
of dabrafenib in patients with BRAFV600E/K-mutant melanoma 
who were previously untreated or had been locally treated 
only for brain metastases.62 Significant clinical activity was 
observed in a cohort of 172 patients, where response rates 
of 39.2% and 30.8% were observed for untreated versus 
locally treated patients, respectively. The toxicity profile 
was manageable, noting the occurrence of pyrexia (6%) and 
squamous cell carcinoma (6%). BREAK-3 (ClinicalTrials.
gov identifier NCT01227889) was a Phase III clinical trial 
evaluating the effects of dabrafenib as compared with dacar-
bazine chemotherapy. This study demonstrated an improve-
ment in progression-free survival as the primary endpoint 
and overall survival as a secondary endpoint.63 The study 
included 250 patients randomized 3:1 to receive dabrafenib, 
with crossover at progression. The median progression-free 
survival for the dabrafenib group was 5.1 months compared 
with 2.7 months for dacarbazine. These data have been 
updated to show a median progression-free survival of 6.9 
months for dabrafenib and 2.7 months for dacarbazine after 
extended follow-up. Overall survival data were initially 
immature, but reported a hazard ratio for survival of 0.61 
(confidence interval 0.25–1.48); however, with subsequent 
follow-up and adjustment for crossover to dabrafenib from 
the dacarbazine arm, an overall survival of 18.2 months was 
observed for dabrafenib as compared with 15.6 months for 
dacarbazine.64 Toxicities were consistent with those observed 
in previous dabrafenib trials.
Trametinib was initially evaluated in a Phase I study 
of patients with advanced solid tumors. In a group of 
206 patients, a recommended Phase II dose of 2 mg per day 
was determined with a response rate of 10% in nonmolecu-
larly selected patients.59 Common adverse events included 
rash and other cutaneous events as well as diarrhea. Dose-
limiting toxicities were cutaneous and gastrointestinal, with 
some ocular events including central serous retinopathy. In Drug, Healthcare and Patient Safety 2014:6 submit your manuscript | www.dovepress.com
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a substudy within this clinical trial, a cohort of patients with 
melanoma was evaluated more specifically.65 Ninety-seven 
patients with melanoma were included and differentiated 
by molecular status including BRAFV600E/K (n=36, of whom 
30 were not previously treated with a BRAF inhibitor), 
BRAF wild-type (n=39), BRAF status unknown (n=6), and 
uveal melanoma (n=16). Among the population of patients 
with tumors harboring BRAF mutations, the response rate 
and median progression-free survival were found to be 33% 
and 5.7 months, respectively. Within the group of patients 
whose tumors were wild-type for BRAF, the response rate 
was 10%, but no responses were observed in seven patients 
with NRAS mutation. Clinical activity of trametinib has also 
been observed in patients non-BRAFV600E/K-mutant melanoma, 
with long-term stable disease observed in two patients with 
BRAFK601E-mutant and BRAFV600R-mutant disease.66 As was 
seen in the total Phase I population, the toxicity profile in 
these trials was predominantly cutaneous and gastrointestinal 
events. The activity observed in patients with BRAF-mutant 
tumors (BRAFV600E/K) was significant enough to recommend 
the pursuit of a Phase III study (METRIC, ClinicalTrials.
gov identifier NCT01245062) comparing trametinib with 
chemotherapy (dacarbazine or paclitaxel).67 This clinical trial 
included 322 patients randomized 2:1 to trametinib and the 
possibility of crossover from chemotherapy to trametinib at 
the time of progression. When considering the intention-to-
treat population, progression-free survival on trametinib was 
4.8 months as compared with 1.5 months on chemotherapy. 
Although the data were not fully mature at the time of report-
ing, the hazard ratio for death significantly favored trametinib 
at 0.54 (95% confidence interval 0.32–0.92), even with the 
consideration that nearly half of patients received trametinib 
in crossover after progression on dacarbazine or paclitaxel. As 
in the Phase I study, common toxicities included cutaneous 
events, diarrhea, and fatigue. Toxicities or events of special 
interest included cardiac-related toxicity, such as a decrease 
in ejection fraction or ventricular dysfunction, which was 
observed in 7% of patients, and ocular toxicity (blurred 
vision or reversible chorioretinopathy) in 9%. Notably, no 
cases of retinal vein occlusion or squamous cell carcinoma 
were observed.
Given that most molecular mechanisms of resistance to 
selective BRAF inhibitors described from patient biopsy 
specimens appear to reactivate signaling through MAPK/
ERK, an interest arose regarding the potential sequencing or 
combining of BRAF and MEK inhibitors. Studies have now 
been reported describing both sequences (BRAF then MEK 
inhibition or MEK then BRAF inhibition); however, neither 
appears to be as efficacious as concurrent BRAF–MEK. 
Regarding the sequence of a BRAF inhibitor followed by 
a MEK inhibitor, patients with BRAF-mutant melanoma 
who had previously been treated with a BRAF inhibitor 
(either vemurafenib or dabrafenib) or with no prior BRAF 
inhibitor exposure were treated in a Phase II study using 
trametinib. Progression-free survival was 4.0 months in the 
BRAF inhibitor-naïve patients as compared with 1.8 months 
in those who had previously received a BRAF inhibitor.66 
The response rate was also markedly different in naïve 
versus BRAF inhibitor-pretreated patients (25% and 0%, 
respectively). Inhibition of MEK by a single agent thus has 
limited value in patients with melanoma after progression 
on a BRAF inhibitor.
The reverse sequence of agents has also been investi-
gated, whereby patients with BRAF-mutant melanoma were 
first treated with a MEK inhibitor and upon progression of 
disease transitioned to a BRAF inhibitor.68 In this retrospec-
tive study of 23 patients, total treatment time was similar to 
that observed using the BRAF followed by MEK inhibitor 
sequence; however, time to progression was similar in both 
groups (4.8 months for trametinib and 4.5 months for dab-
rafenib). This sequence of agents was observed to achieve a 
higher rate of response to MEK inhibition when given first 
(39%).
As compared with the sequencing approach of BRAF and 
MEK inhibitors, upfront combination of BRAF and MEK 
inhibitors appears to be more promising. A Phase I/II study 
explored the combination of dabrafenib and trametinib, even-
tually describing respective combination doses of 150 mg 
twice per day and 2 mg daily as tolerable. All patients in 
this study had advanced melanoma harboring mutations in 
BRAFV600E/K. Combination treatment at 150 mg and 2 mg as 
well as 150 mg and 1 mg were compared with dabrafenib 
150 mg twice per day. In the 150/2 arm, a significant improve-
ment in both response rate (76% versus 54%, P=0.03) and 
progression-free survival (9.4 versus 5.8 months, hazard 
ratio 0.39; 95% confidence interval 0.25–0.62; P,0.001) was 
observed when compared with dabrafenib monotherapy.17 
The combination treatment arm demonstrated fewer adverse 
events as compared with the dabrafenib monotherapy arm, eg, 
for squamous cell carcinoma (7% versus 19%, respectively), 
although the incidence of pyrexia (71% versus 26%) was 
increased. These data formed the basis for the FDA approval 
of this combination therapy.
Mature data from the Phase III clinical trial evaluating 
dabrafenib plus trametinib as compared with dab-
rafenib plus placebo are eagerly awaited. A preliminary Drug, Healthcare and Patient Safety 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
84
Luke and Ott
Table 1 Combination BRAF or BRAF–MeK with immunotherapy studies relevant to patients with melanoma
Phase Drug (molecular target) Immunotarget (drug) ClinialTrials.gov  
identifier
Sponsor
i Dabrafenib–trametinib (BRAF–MeK) CTLA-4 (ipilimumab – concurrent) NCT01767454 GlaxoSmithKline
i Dabrafenib–trametinib (BRAF–MeK) CTLA-4 (ipilimumab – sequential) NCT01940809 NCi-CTeP (Dana-Farber 
Cancer institute)
i Dabrafenib–trametinib (BRAF–MeK) PD-L1 (MeDi4736) NCT02027961 Medimmune
i Dabrafenib–trametinib (BRAF–MeK) PD-1 (MK-3475) Not yet registered Merck
i vemurafenib-DNe3 (BRAF–AKT) CTLA-4 (ipilimumab) NCT02095652 Cancer Centre of 
Monoclonal Therapy
ib vemurafenib (BRAF) PD-L1 (MPDL3280A) NCT01656642 Hoffman-La Roche
ib Cobimetinib (MeK) PD-L1 (MPDL3280A) NCT01988896 Hoffman-La Roche
ii vemurafenib (BRAF) CTLA-4 (ipilimumab – sequential) NCT01673854 Bristol-Myers Squibb
Table 2 Clinical trials evaluating BRAF and MeK inhibitors in combination
Phase Drug name Target (treatment indication  
or trial name)
ClinialTrials. 
gov identifier
Sponsor
i LY3009120 BRAF (paradox breaker) NCT02014116 eli Lilly
i Dabrafenib, trametinib, DNe3 BRAF–MeK–AKT NCT02087254 Cancer Centre of Monoclonal 
Therapy
i AT13387, dabrafenib,  
and trametinib
BRAF–MeK–Hsp90 NCT02097225 NCi-CTeP (Massachusetts  
General Hospital)
i Dabrafenib, trametinib BRAF–MeK (brain metastases) NCT01978236 GlaxoSmithKline
i LGX818 + MeK162, BKM120,  
Lee011, BGJ398, iNC280
BRAF + MeK, Pi3K, CDK4, FGFR,  
MeT (LOGiC)
NCT01820364 Novartis
i PLX8394 BRAF (paradox breaker) NCT02012231 Plexxikon
i vemurafenib, cobimetinib,  
ornatuzumab
BRAF–MeK–MeT NCT01974258 Hoffman-La Roche
i/ii Dabrafenib, trametinib, navitoclax BRAF–MeK–Bcl2 NCT01989585 NCi-CTeP (Massachusetts  
General Hospital)
i/ii Dabrafenib, trametinib BRAF–MeK (Japanese patients) NCT01928940 GlaxoSmithKline
i/ii vemurafenib, cobimetinib,  
ganetespib
BRAF–MeK–Hsp90 Not yet  
registered
Alliance for Clinical Trials in Oncology 
(Dana-Farber Cancer institute)
ib/ii LGX818, MeK162 BRAF–MeK NCT01543698 Novartis
ii Dabrafenib, trametinib BRAF–MeK (brain metastases) NCT02039947 GlaxoSmithKline
ii Dabrafenib, trametinib BRAF–MeK (brain metastases) NCT01619774 MD Anderson Cancer Center
ii Dabrafenib, trametinib BRAF–MeK (neoadjuvant) NCT01972347 Melanoma institute of Australia
ii Dabrafenib, trametinib BRAF versus BRAF–MeK (neoadjuvant) NCT01701037 GlaxoSmithKline
iii Dabrafenib, trametinib (COMBi-AD) BRAF–MeK (adjuvant) NCT01682083 GlaxoSmithKline
iii Dabrafenib, trametinib, vemurafenib BRAF–MeK versus BRAF NCT01597908 GlaxoSmithKline
iii LGX818, MeK162, vemurafenib BRAF versus BRAF–MeK (COLUMBUS) NCT01909453 Novartis
iii vemurafenib, cobimetinib BRAF versus BRAF–MeK (co-BRiM) NCT01689519 Hoffman-La Roche
Abbreviations: LOGiC, LGX818 in Combination with Agents (MeK162; BKM120; Lee011; BGJ398; iNC280) in Advanced BRAF Melanoma; COLUMBUS, Study Comparing 
Combination of LGX818 Plus MeK162 and LGX818 Monotherapy versus vemurafenib in BRAF Mutant Melanoma; co-BRiM, A Phase 3 Study Comparing GDC-0973 
(Cobimetinib), a MeK inhibitor, in Combination with vemurafenib vs vemurafenib Alone in Patients with Metastatic Melanoma.
communication in January 2014 reported that the primary 
endpoint of progression-free survival had been met. An ini-
tial description included a median progression-free survival 
of 9.3 months for combination therapy as compared with 
8.8 months with dabrafenib (hazard ratio 0.75, P=0.035). 
The response rate for the combination treatment was 
reported to be 67% as compared with 51% for dabrafenib. 
Toxicity was described as similar to the Phase II results, 
although a decrease in total pyrexia events was described 
(51% in Phase III versus 70% in Phase II). Overall survival 
data are not yet mature.69
Patient-focused perspectives: quality 
of life and patient satisfaction
The development of selective BRAF inhibitors marked 
a shift away from standard chemotherapeutic approaches 
for the management of BRAF-mutant melanoma. This 
clearly led to a reduction in the toxicities associated with Drug, Healthcare and Patient Safety 2014:6 submit your manuscript | www.dovepress.com
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chemo  therapy; however, a new spectrum of cutaneous 
adverse events, including rash, photosensitivity, and develop-
ment of keratoacanthoma and squamous cell carcinoma, was 
observed. Overall these toxicities seem to be more tolerable 
for patients. Additionally, a quality of care analysis suggested 
more than a doubling of quality-adjusted life years by vemu-
rafenib treatment relative to the prior standard of care.70
Whether the combination of dabrafenib and trametinib 
will demonstrate an improvement in quality of life as com-
pared with vemurafenib (or dabrafenib alone) is still an open 
question. Although BRAF plus MEK inhibition decreases the 
cutaneous toxicity substantially, treatment with dabrafenib 
plus trametinib has demonstrated a different set of toxicities. 
The primary problematic toxicity with dabrafenib is pyrexia, 
which in some patients can be intolerable. Although many 
patients experience an initial episode of pyrexia that resolves 
with a drug holiday and dabrafenib rechallenge without any 
issues,71 other patients have to discontinue the drug altogether. 
Class effect MEK inhibitor toxicities must be taken into 
consideration for trametinib. These predominantly include an 
acneiform rash, edema, and gastrointestinal events (diarrhea 
and nausea), but can also include more serious toxicities, such 
as ocular (central serous retinopathy) and cardiac (decreased 
ejection fraction) toxicities. Algorithms for the management 
of these adverse events have been developed in parallel with 
the clinical trials; however, their applicability in the general 
oncology practice setting has yet to be tested.
No studies to date have assessed quality of life parameters 
or patient satisfaction of dabrafenib plus trametinib as com-
pared with chemotherapy or BRAF inhibition alone. This is 
likely to be an important issue, especially if overall survival 
on the two-drug combination is not improved in a manner that 
is clinically impressive as compared with current standards 
of care. The available data to date suggest that dabrafenib 
plus trametinib improves progression-free survival, but 
overall survival has not yet been clearly demonstrated, and 
long-term tolerability of the combination may be a contribut-
ing factor. This issue will likely play out in the next several 
years as longer-term, real-world experience provides insight 
into patient perspectives and other treatments for melanoma 
become standard practice.
Conclusion
Given the impressive tumor responses, and progression-free 
and overall survival benefit associated with treatment with a 
selective BRAF inhibitor, it is clear that this approach is now a 
cornerstone in the management of patients with BRAF-mutant 
melanoma. The development of dabrafenib plus trametinib has 
now improved upon that in terms of both response rate and 
progression-free survival and seems likely to also improve 
overall survival. Nevertheless, whether combined BRAF–
MEK inhibition with dabrafenib plus trametinib will displace 
single-agent BRAF inhibition entirely is yet to be determined 
and may depend on the clinical circumstance in which this 
treatment is being utilized. Although the study of BRAF and 
MAPK inhibition with selective BRAF and MEK inhibitors has 
been an exciting development in the field of melanoma thera-
peutics, on a parallel time course, major advancements have 
been made in immunotherapeutics with immune-checkpoint 
blockade. These advances have included FDA approval of the 
anti-CTLA4 antibody ipilimumab, and the likely approval of 
anti-PD1 antibodies, MK-3475, and nivolumab in the near 
future. Whereas targeted therapies such as BRAF and MEK 
inhibitors have a high response rate but modest progression-
free survival, immunotherapies have the potential for durable 
disease control in a higher number of patients. Ipilimumab 
notably has a much lower response rate and longer time to 
onset of efficacy as compared with BRAF inhibition.8 The 
response rate of anti-PD1 antibodies is higher, however, and 
demonstrate a much more rapid onset of activity compared 
with ipilimumab.72,73 Further, combination approaches using 
existing immunotherapies (anti-CTLA4 plus anti-PD1)74 and 
potentially other novel approaches (eg, anti-KIR, anti-LAG3, 
anti-OX40) have the potential to increase the response rate and 
durable disease control rates even further.75
An important consideration for the future role of 
BRAF and MAPK inhibition must then include the most 
effective combination or sequence of both targeted and 
  immunotherapies. A robust body of data suggests that 
combining a BRAF inhibitor with immunotherapy in some 
fashion is likely to be efficacious.76 However, the initial 
attempt to combine vemurafenib with ipilimumab had to be 
aborted due to high rates of immune-mediated hepatitis.77 
Beyond this, laboratory experiments suggest that MEK inhi-
bition is likely to have immune-dampening effects and thus 
may not be an appropriate targeted therapy to combine with 
immunotherapy.78 Thus, at this time, it is unclear whether 
targeted therapies may be synergistic or antagonistic with 
immunotherapy.79 Table 1 describes ongoing clinical trials 
examining the combination of BRAF and/or MEK inhibitors 
with immunotherapy.
Another important issue when considering BRAF inhibitor 
monotherapy or treatment with dabrafenib plus trametinib will 
be the potential toxicity and quality of life for the patient. In 
a robust patient, it is likely that the absolute improvement in 
response rate and progression-free survival would be enough Drug, Healthcare and Patient Safety 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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to drive a treatment choice with dabrafenib and trametinib. 
However, in a patient of lesser performance status who would 
be less able to tolerate pyrexia or in a patient who has pre-
existing gastrointestinal, ocular, or cardiac toxicity, treatment 
with a single-agent BRAF inhibitor may be   preferable. It is also 
worth noting that other BRAF–MEK inhibitor combinations, 
as well as “paradox-breaker” RAF inhibitors that both block 
mutant BRAF and mitigate physiologic signaling through other 
RAF isoforms, are in clinical development. The side effect 
profiles of these other approaches and their clinical efficacy 
as compared with BRAF inhibitor monotherapy as well as 
dabrafenib plus trametinib will also significantly influence 
appropriate sequencing or combinations of available drugs. 
Table 2 describes ongoing clinical trials examining other 
BRAF inhibitors and BRAF–MEK inhibitor combinations.
It is clearly an exciting time in the field of melanoma 
therapeutics. Nevertheless, many questions remain regard-
ing combining and sequencing agents, in order to obtain 
the greatest long-term benefit for patients, in addition to the 
investigation of novel agents. As such, participation in a clini-
cal trial should be offered to all patients when possible, as 
while many options exist, there is not yet a defined standard 
of care. For a patient who is not a candidate for a clinical 
trial, the front-line standard of care is debatable; however, 
we would advocate that all patients who have the opportunity 
be treated first with immunotherapy, given the potential for 
long-term disease control with this approach. In those patients 
who progress through immunotherapy, are not candidates 
for such treatment, or have rapidly progressive disease that 
necessitates immediate palliation, treatment with dabrafenib 
plus trametinib is emerging as an efficacious option in the 
management of BRAF-mutant advanced melanoma.
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